Changzhou Qianhong Biopharma Co (SZSE:002550) Total Liabilities : ¥296 Mil (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Changzhou Qianhong Biopharma Co Total Liabilities?

Changzhou Qianhong Biopharma Co's Total Liabilities for the quarter that ended in Mar. 2024 was ¥296 Mil.

Changzhou Qianhong Biopharma Co's quarterly Total Liabilities increased from Sep. 2023 (¥258.95 Mil) to Dec. 2023 (¥292.17 Mil) and increased from Dec. 2023 (¥292.17 Mil) to Mar. 2024 (¥295.56 Mil).

Changzhou Qianhong Biopharma Co's annual Total Liabilities declined from Dec. 2021 (¥390.24 Mil) to Dec. 2022 (¥372.53 Mil) and declined from Dec. 2022 (¥372.53 Mil) to Dec. 2023 (¥292.17 Mil).

Changzhou Qianhong Biopharma Co Total Liabilities Historical Data

The historical data trend for Changzhou Qianhong Biopharma Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Changzhou Qianhong Biopharma Co Total Liabilities Chart

Changzhou Qianhong Biopharma Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

601.65

386.35

390.24

372.53

292.17

Changzhou Qianhong Biopharma Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															549.35	560.32	258.95	292.17	295.56

Changzhou Qianhong Biopharma Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Changzhou Qianhong Biopharma Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	205.811	+	(0	+	86.362
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	292

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	2766.081	-	2473.908
	=	292

Changzhou Qianhong Biopharma Co's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	208.266	+	(0	+	87.293
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	296

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	2728.721	-	2433.162
	=	296

Changzhou Qianhong Biopharma Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Changzhou Qianhong Biopharma Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Changzhou Qianhong Biopharma Co (SZSE:002550) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Changzhou Qianhong Biopharma Co Ltd (SZSE:002550) » Definitions » Total Liabilities

Traded in Other Exchanges

N/A

Address

Number 90 Changjiang Middle Road, Xinbei distract, Jiangsu Province, Changzhou, CHN, 213022

Website

http://www.qhsh.com.cn

Changzhou Qianhong Biopharma Co Ltd engages in the research and development, production, and sale of biopharmaceutical products with the focus on polysaccharides and enzymes in China. The company provides various products, including heparin sodium, heparin calcium, enoxaparin sodium, nadroparin calcium, and dalteparin sodium for use as anticoagulants; pancreatin for use as a digestive agent; asparaginase for use as an antineoplastic agent; and kallidinogenase kallikrein and heparinoid.

Changzhou Qianhong Biopharma Co (SZSE:002550) Headlines

No Headlines